Related Experiment Video

Updated: Aug 21, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

Expression and activities of several drug-metabolizing enzymes in LLC-PK1 cells

Raymond J Gonzalez1, Joan B Tarloff

  • 1Division of Pharmacology and Toxicology, Department of Pharmaceutical Sciences, University of the Sciences in Philadelphia, 600 South 43rd Street, Philadelphia, PA 19104, USA.

Toxicology in Vitro : an International Journal Published in Association with BIBRA
|October 7, 2004
PubMed

Insights

LLC-PK1 cells show very low drug-metabolizing enzyme activity, significantly less than rat liver and kidney tissues. This indicates limited capacity for xenobiotic metabolism in these commonly used toxicology research cells.

Area of Science:

  • Biochemistry
  • Toxicology
  • Cell Biology

Background:

  • LLC-PK1 cells are widely utilized in toxicology research.
  • Limited information exists regarding their xenobiotic metabolism capabilities.

Purpose of the Study:

  • To investigate the expression and activity of key drug-metabolizing enzymes in LLC-PK1 cells.
  • To compare these activities with those found in rat liver and kidney tissues.

Main Methods:

  • Enzyme activity assays were performed on S9 fractions from LLC-PK1 cells, rat liver, and rat kidney.
  • Specific substrates and inhibitors were used to measure activities of cytochromes P450 (CYP 1A1/1A2, CYP 2E1), flavin monooxygenase (FMO), 5-lipoxygenase (5-LO), and cyclooxygenase-1 (COX-1).
  • Western blot analysis was conducted to confirm enzyme expression.

Main Results:

  • Rat liver S9 fractions exhibited the highest levels of all five enzyme activities.
  • LLC-PK1 cells demonstrated significantly lower enzyme activities compared to rat liver and generally less than rat kidney.
  • Enzyme inhibitors confirmed the enzymatic basis of product formation, and Western blots supported the low enzyme activity findings in LLC-PK1 cells.

Conclusions:

  • LLC-PK1 cells possess very low levels of drug-metabolizing enzyme activities.
  • These findings suggest a limited capacity for xenobiotic metabolism in LLC-PK1 cells, which is crucial for their application in toxicology research.

More Related Videos

Exploring the Regulation of Lipid Droplet Catabolism through Lipophagy07:20

Exploring the Regulation of Lipid Droplet Catabolism through Lipophagy

Published on: January 31, 2025

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Drug Metabolism: Phase II Reactions01:14

Drug Metabolism: Phase II Reactions

Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion, mediated...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...